These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1876437)

  • 1. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group.
    Ferrari MD; Wilkinson M; Hirt D; Lataste X; Notter M;
    Pain; 1991 Jun; 45(3):283-291. PubMed ID: 1876437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
    Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
    Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
    Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
    Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
    Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
    Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.
    Cabarrocas X;
    Clin Ther; 2001 Nov; 23(11):1867-75. PubMed ID: 11768838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT3 receptor antagonists and migraine therapy.
    Ferrari MD
    J Neurol; 1991; 238 Suppl 1():S53-6. PubMed ID: 2045832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder.
    Lecrubier Y; Puech AJ; Azcona A; Bailey PE; Lataste X
    Psychopharmacology (Berl); 1993; 112(1):129-33. PubMed ID: 7871001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the 5-HT3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity.
    Stacher G; Bergmann H; Schneider C; Steiner-Mittelbach G; Gaupmann G; Steinringer H; Abatzi TA; Stacher-Janotta G
    Br J Clin Pharmacol; 1990 Jul; 30(1):41-8. PubMed ID: 2390431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
    Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
    Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
    Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
    Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divalproex sodium in migraine prophylaxis: a dose-controlled study.
    Klapper J
    Cephalalgia; 1997 Apr; 17(2):103-8. PubMed ID: 9137847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
    Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
    Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
    Brandes JL; Visser WH; Farmer MV; Schuhl AL; Malbecq W; Vrijens F; Lines CR; Reines SA;
    Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group.
    Visser WH; Ferrari MD; Bayliss EM; Ludlow S; Pilgrim AJ
    Cephalalgia; 1992 Oct; 12(5):308-13. PubMed ID: 1330318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group.
    Bousser MG; D'Allens H; Richard A
    J Intern Med; 1993 Aug; 234(2):211-6. PubMed ID: 8393474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
    CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men.
    Stacher G; Gaupmann G; Schneider C; Stacher-Janotta G; Steiner-Mittelbach G; Abatzi TA; Steinringer H
    Br J Clin Pharmacol; 1989 Sep; 28(3):315-22. PubMed ID: 2789925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?
    Stratz T; Kees F; Müller W
    Drugs Exp Clin Res; 2003; 29(2):91-4. PubMed ID: 12951840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.